On the stock market since 1997, it operates in the world of health and science. It has 268 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 65% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 8% a year on average.
Sales run at $206.1M a year. A small number, but proof the product has real buyers.
The average analyst price target is $4.00 — 43% above today’s price.
A loss of $15.6M against $206.1M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 8/100.
On our five-subject report card, CERS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CERS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (59/100) says the stock isn’t cheap.